N/A N=20 Randomized Treatment

MS Spinal Mobilisation Study

Multiple Sclerosis

Bottom Line

View on ClinicalTrials.gov: NCT05090709 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2024

Primary outcome: Primary: Participant Muscle Stiffness Measure — 350.83; 240.07 Newton-metres

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Spinal Mobilisation Intervention (Other); General Massage (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Edinburgh Napier University
Primary completion: Apr 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Participant Muscle Stiffness Measure	324.37; 220.27	> 0.05
PRIMARY Participant Muscle Stiffness Measure	324.37; 220.27	> 0.05
PRIMARY Participant Muscle Stiffness Measure	324.37; 220.27	> 0.05
PRIMARY Participant Muscle Stiffness Measure	324.37; 220.27	> 0.05
PRIMARY Participant Muscle Stiffness Measure	324.37; 220.27	> 0.05
PRIMARY Participant Single Leg Stance Body Sway Path Length	389.22; 491.92	< 0.05 sig
PRIMARY Participant Single Leg Stance Body Sway Path Length	389.22; 491.92	< 0.05 sig
PRIMARY Participant Single Leg Stance Body Sway Path Length	389.22; 491.92	< 0.05 sig
PRIMARY Participant Single Leg Stance Body Sway Path Length	389.22; 491.92	< 0.05 sig
PRIMARY Participant Single Leg Stance Body Sway Path Length	389.22; 491.92	< 0.05 sig
PRIMARY Participant Sit-to-Stand Velocity	164.18; 145.06	> 0.05
PRIMARY Participant Sit-to-Stand Velocity	164.18; 145.06	> 0.05
PRIMARY Participant Sit-to-Stand Velocity	164.18; 145.06	> 0.05
PRIMARY Participant Sit-to-Stand Velocity	164.18; 145.06	> 0.05
PRIMARY Participant Sit-to-Stand Velocity	164.18; 145.06	> 0.05
PRIMARY Participant Pain Score - Visual Analogue Scale (VAS)	0.5; 0.3	> 0.05
PRIMARY Participant Pain Score - Visual Analogue Scale (VAS)	0.5; 0.3	> 0.05
PRIMARY Participant Pain Score - Visual Analogue Scale (VAS)	0.5; 0.3	> 0.05
PRIMARY Participant Pain Score - Visual Analogue Scale (VAS)	0.5; 0.3	> 0.05
PRIMARY Participant Pain Score - Visual Analogue Scale (VAS)	0.5; 0.3	> 0.05
PRIMARY Participant Fatigue Score - 5 Item Modified Fatigue Impact Scale.	6.6; 7.4	< 0.05 sig
PRIMARY Participant Fatigue Score - 5 Item Modified Fatigue Impact Scale.	6.6; 7.4	< 0.05 sig
SECONDARY Participant Muscle Tone Measure	14.86; 12.32	> 0.05
SECONDARY Participant Muscle Tone Measure	14.86; 12.32	> 0.05
SECONDARY Participant Muscle Tone Measure	14.86; 12.32	> 0.05
SECONDARY Participant Muscle Tone Measure	14.86; 12.32	> 0.05
SECONDARY Participant Muscle Tone Measure	14.86; 12.32	> 0.05
SECONDARY Participant Muscle Elasticity Measure	1.43; 1.36	> 0.05
SECONDARY Participant Muscle Elasticity Measure	1.43; 1.36	> 0.05
SECONDARY Participant Muscle Elasticity Measure	1.43; 1.36	> 0.05
SECONDARY Participant Muscle Elasticity Measure	1.43; 1.36	> 0.05
SECONDARY Participant Muscle Elasticity Measure	1.43; 1.36	> 0.05
SECONDARY Participant Single Leg Stance Body Sway Anterior-Posterior Path Length	279.76; 323.6	> 0.05
SECONDARY Participant Single Leg Stance Body Sway Anterior-Posterior Path Length	279.76; 323.6	> 0.05
SECONDARY Participant Single Leg Stance Body Sway Anterior-Posterior Path Length	279.76; 323.6	> 0.05
SECONDARY Participant Single Leg Stance Body Sway Anterior-Posterior Path Length	279.76; 323.6	> 0.05
SECONDARY Participant Single Leg Stance Body Sway Anterior-Posterior Path Length	279.76; 323.6	> 0.05
SECONDARY Participant Single Leg Stance Body Sway Medial-Lateral Path Length	205.69; 296.17	< 0.05 sig
SECONDARY Participant Single Leg Stance Body Sway Medial-Lateral Path Length	205.69; 296.17	< 0.05 sig
SECONDARY Participant Single Leg Stance Body Sway Medial-Lateral Path Length	205.69; 296.17	< 0.05 sig
SECONDARY Participant Single Leg Stance Body Sway Medial-Lateral Path Length	205.69; 296.17	< 0.05 sig
SECONDARY Participant Single Leg Stance Body Sway Medial-Lateral Path Length	205.69; 296.17	< 0.05 sig
SECONDARY Participant Single Leg Stance Body Sway Velocity	38.57; 48.77	> 0.05
SECONDARY Participant Single Leg Stance Body Sway Velocity	38.57; 48.77	> 0.05
SECONDARY Participant Single Leg Stance Body Sway Velocity	38.57; 48.77	> 0.05
SECONDARY Participant Single Leg Stance Body Sway Velocity	38.57; 48.77	> 0.05
SECONDARY Participant Single Leg Stance Body Sway Velocity	38.57; 48.77	> 0.05
SECONDARY Participant Sit-to-Stand Rising Index	59.06; 61.53	> 0.05
SECONDARY Participant Sit-to-Stand Rising Index	59.06; 61.53	> 0.05
SECONDARY Participant Sit-to-Stand Rising Index	59.06; 61.53	> 0.05
SECONDARY Participant Sit-to-Stand Rising Index	59.06; 61.53	> 0.05
SECONDARY Participant Sit-to-Stand Rising Index	59.06; 61.53	> 0.05
SECONDARY Participant Sit-to-Stand Weight Transfer	2.44; 2	< 0.05 sig
SECONDARY Participant Sit-to-Stand Weight Transfer	2.44; 2	< 0.05 sig
SECONDARY Participant Sit-to-Stand Weight Transfer	2.44; 2	< 0.05 sig
SECONDARY Participant Sit-to-Stand Weight Transfer	2.44; 2	< 0.05 sig
SECONDARY Participant Sit-to-Stand Weight Transfer	2.44; 2	< 0.05 sig

Summary

The objective of the study is to measure the effect of a spinal mobilisation intervention on para-spinal muscle tissue quality, functional balance measures, pain and fatigue in people with multiple sclerosis. The mobilisation intervention group will be compared to a general massage group to analyse the difference between the specificities of the intervention compared to general manual touch. Participants will be randomly allocated to a group condition for a between-subject, repeated measures study. The study hypothesises a decrease in lumbar stiffness, body sway, pain and fatigue post the intervention compared to the general massage group.

Eligibility Criteria

Inclusion Criteria

Must have Multiple Sclerosis diagnosis.
Must be able to walk independently.
Must have an EDSS score of 6 or below.

Exclusion Criteria

Respond positively to any absolute contraindications for spinal manual therapy including:

segment instability
infectious disease
osteomyelitis
bone tumours
severe haemophilia
spinal cord damage
cervical arterial dysfunction

Respond positively to any relative contraindications for spinal manual therapy including:

spinal disc prolapse
spondylosis
inflammatory arthritides
osteoporosis
hypermobile syndrome
pregnancy
pregnancy
cancer
cardiovascular disease
respiratory disease
healing injury
adverse reaction to previous spinal treatment.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05090709). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.